NCT02825160View on ClinicalTrials.gov

Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)

CompletedOBSERVATIONAL
Enrollment

282

Participants

Timeline

Start Date

August 1, 2016

Primary Completion Date

March 31, 2023

Study Completion Date

September 27, 2023

Conditions
Hypertension, Pulmonary
Interventions
DRUG

Ventavis (Iloprost, BAYQ6256)

The treatment of Ventavis should comply with the local product information

Trial Locations (1)

Unknown

Many Locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY